Results 11 to 20 of about 562,472 (163)

Long-Term Effect of Sodium Oxybate (Xyrem®) in Spasmodic Dysphonia with Vocal Tremor [PDF]

Tremor and Other Hyperkinetic Movements, 2013
Background: Symptoms of spasmodic dysphonia (SD) are usually managed successfully with botulinum toxin injections. Vocal tremor (VT), which accompanies SD, has a poor response to this treatment.Case Report: We report a case of a female with SD and VT who
Kristina Simonyan, Steven J. Frucht
doaj   +2 more sources

Practical Guidance for Initiation and Management of Patients on Once-Nightly Sodium Oxybate for Narcolepsy Treatment: Modified Delphi Panel Consensus Recommendations [PDF]

Neurology and Therapy
Introduction Despite its strong recommendation for treatment of excessive daytime sleepiness (EDS), cataplexy, and disease severity associated with narcolepsy by the American Academy of Sleep Medicine, sodium oxybate (SXB) remains underutilized.
Monique Mulvany, Ellen Wermter, Maggie Lavender, Heidy Merius, Cecile Martin, Amber Burns, Jamie Simmons   +6 more
doaj   +2 more sources

Understanding the Patient Experience with Twice-Nightly Sodium Oxybate Therapy for Narcolepsy: A Social Listening Experiment [PDF]

Brain Sciences
Background/Objectives: Narcolepsy is a chronic neurologic disorder associated with substantial challenges that affect the social, emotional, and financial quality-of-life domains. A social listening analysis and structured survey were conducted to better
Maria Picone, Frederik Ascencion, Matthew Horsnell, Enming Zhang, Lauren Dougherty, Christopher DeFelice, Maurice Flurie, Rachelle Cook, Anne Marie Morse, Luis E. Ortiz, E. Robert Wassman, Jennifer Gudeman   +11 more
doaj   +2 more sources

Sodium Oxybate as a Potential New Treatment for Catatonia in Patients With Depression, Bipolar Disorder, or a Psychotic Disorder: Protocol for a Randomized Controlled Trial [PDF]

JMIR Research Protocols
BackgroundCatatonia is a severe psychomotor syndrome predominantly associated with depressive, bipolar, and psychotic disorders.
Lilian Bot, Josine G van Mill, Laetitia J C A Smarius, Adriaan W Hoogendoorn, Bram W C Storosum, Christiaan H Vinkers, Gabriel E Jacobs, Gert Jan Lammers, Hanna M Heller, Jantine C A Colen-de Koning, Joris J B van der Vlugt, Marloes S Oudijn, Martijn S van Noorden, Pierre M Bet, Rolf Fronczek, Heleen S van der Heijden, Sjors M M Lange, Ysbrand D van der Werf, Eric R van Exel   +18 more
doaj   +2 more sources

Dosing Optimization of Low-Sodium Oxybate in Narcolepsy and Idiopathic Hypersomnia in Adults: Consensus Recommendations [PDF]

Neurology and Therapy
Introduction Low-sodium oxybate (LXB) is approved for treatment of narcolepsy in patients aged 7 years and older and treatment of idiopathic hypersomnia in adults. LXB contains the same active moiety with 92% less sodium than sodium oxybate (SXB). As the
Anne Marie Morse, Richard K. Bogan, Asim Roy, Michael J. Thorpy   +3 more
doaj   +2 more sources

How once-nightly sodium oxybate is processed in the body in healthy volunteers: a plain language summary [PDF]

Journal of Comparative Effectiveness Research
What is this summary about? This is a plain language summary of an article originally published in the journal Sleep Medicine. Narcolepsy is a sleep condition in which people have periods of extreme sleepiness during the day.
Richard Bogan, Michael J Thorpy, Sarah Berkowitz, Jennifer Gudeman   +3 more
doaj   +2 more sources

A Patient-centric Clinical Trial Design to Comprehensively Evaluate Low-Sodium Oxybate in People with Idiopathic Hypersomnia or Narcolepsy [PDF]

Neurology and Therapy
Introduction Low-sodium oxybate (LXB; Xywav®) is approved to treat idiopathic hypersomnia in adults and excessive daytime sleepiness or cataplexy in individuals aged ≥ 7 years with narcolepsy.
Deborah A. Nichols, Teresa L. Steininger, Douglas S. Fuller, M. Todd Kirby, Emily C. Barker, Marisa Whalen, Jessica K. Alexander, Sarah Akerman, David T. Plante   +8 more
doaj   +2 more sources

Sodium oxybate – new views on an old candidate This presentation will outline the outcome of a clinical development program, including a Phase 3 study, on sodium oxybate in the treatment of alcohol dependence [PDF]

European Psychiatry
Sodium oxybate (SMO) has shown efficacy in the treatment of alcohol withdrawal syndrome (AWS) and in the maintenance of abstinence in alcohol dependent (AD) patients in a series of pilot randomized controlled trials.
J. Guiraud
doaj   +2 more sources

Cataplexy response with extended-release once-nightly sodium oxybate: Post hoc responder analyses from the phase 3 REST-ON clinical trial [PDF]

Sleep Medicine: X
Background: Once-nightly sodium oxybate (ON-SXB), an extended-release oxybate formulation, yielded significant (P 
Michael J. Thorpy, Clete A. Kushida, Richard Bogan, Akinyemi O. Ajayi, Bruce C. Corser, Jennifer Gudeman   +5 more
doaj   +2 more sources

Criteria for Gauging Response to Sodium Oxybate for Narcolepsy [PDF]

, 2017
Our objective was to define responder criteria using an anchor-based approach for frequency of cataplexy attacks and excessive daytime sleepiness in narcolepsy patients undergoing sodium oxybate treatment. We used pooled data from two randomized, placebo-
Chinglin Lai (5169872), Terri E. Weaver (7931498), Alana D. Steffen (7931495)   +2 more
core   +6 more sources